Correlation Between ABVC Biopharma and Mineralys Therapeutics,

Can any of the company-specific risk be diversified away by investing in both ABVC Biopharma and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining ABVC Biopharma and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between ABVC Biopharma and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on ABVC Biopharma and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in ABVC Biopharma with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of ABVC Biopharma and Mineralys Therapeutics,.

Diversification Opportunities for ABVC Biopharma and Mineralys Therapeutics,

0.29

Correlation Coefficient

ABVC Biopharma  Mineralys Therapeutics,

Modest diversification

The 3 months correlation between ABVC and Mineralys is 0.29. Overlapping area represents the amount of risk that can be diversified away by holding ABVC Biopharma and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and ABVC Biopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on ABVC Biopharma are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of ABVC Biopharma i.e., ABVC Biopharma and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between ABVC Biopharma and Mineralys Therapeutics,

Given the investment horizon of 90 days ABVC Biopharma is expected to generate 1.33 times more return on investment than Mineralys Therapeutics,. However, ABVC Biopharma is 1.33 times more volatile than Mineralys Therapeutics, Common. It trades about 0.1 of its potential returns per unit of risk. Mineralys Therapeutics, Common is currently generating about -0.02 per unit of risk. If you would invest  55.00  in ABVC Biopharma on October 5, 2024 and sell it today you would earn a total of  4.00  from holding ABVC Biopharma or generate 7.27% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

ABVC Biopharma  vs.  Mineralys Therapeutics, Common

ABVC Biopharma

Risk-Adjusted Performance

3 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in ABVC Biopharma are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, ABVC Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point.

Mineralys Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Mineralys Therapeutics, is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with ABVC Biopharma and Mineralys Therapeutics,

The main advantage of trading using opposite ABVC Biopharma and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if ABVC Biopharma position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.

The idea behind ABVC Biopharma and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.